IL4 and atopic eczema: Therefore, our patient’s current management lacks the use of oral systemic steroids, and is ultimately leading to the addition of dupilumab, which is approved in the United States as an independent therapy for moderate-to-severe atopic dermatitis. Dupilumab is a monoclonal antibody targeting interleukin-4 and -13, two cytokines that are crucial in the inflammatory process of diseases such as atopic dermatitis and asthma.